New York, Jan 31, 2026, 10:48 EST — Market closed
AbbVie Inc. shares climbed 1.17% to close at $223.01 on Friday, outperforming the broader market. Investors are gearing up for the drugmaker’s upcoming earnings report next week. (Nasdaq)
U.S. stocks dipped as Donald Trump nominated Kevin Warsh to replace Jerome Powell at the Federal Reserve, with investors also digesting earnings reports and a producer price inflation signal. The Dow dropped 0.36%, the S&P 500 lost 0.43%, and the Nasdaq slid 0.94%. “Markets are calibrating” to the Warsh appointment, said Michael Hans of Citizens Wealth. (Reuters)
In big pharma, the action was uneven. Pfizer gained 1.30%, but Amgen dipped 0.31%, and Johnson & Johnson held steady. AbbVie remains roughly 9% under its 52-week peak, with Friday’s volume coming in above its 50-day average. (MarketWatch)
Following the close, the stock hovered near $223, showing little movement and no obvious sign of new company news heading into the weekend. (MarketWatch)
All eyes are on what’s next, not Friday’s action. Investors want to see if AbbVie’s newer immunology drugs can sustain sales enough to counter Humira’s decline, as biosimilars—cheaper copies of complex biologics—continue to take their toll.
Guidance could carry more weight than the quarterly results. Traders are looking for a clear picture of management’s outlook on 2026 demand, pricing, and spending, especially following recent volatility in the stock toward the end of the month.
On the flip side, the risks stand out clearly. Any hint of a weaker outlook, tighter pricing pressure, or slowing growth drivers could send shares tumbling fast—especially with markets already jittery over rates and political noise.
AbbVie is set to report its full-year and fourth-quarter results early Wednesday, Feb. 4, before the market opens. The company will follow up with an earnings call at 8 a.m. Central time. (Abbvie)
